TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Syndax Pharmaceuticals Inc (SNDX)

Healthcare Biotechnology
19.10 $
-2.2% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Syndax Pharmaceuticals Inc (SNDX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.8% of the shares are freely tradable; institutional investors hold 116.0%.

Ownership Structure

Institutional ownership
116.0%
Insiders
1.7%
Float
89.8%
Short % of float
23.9%
Shares Outstanding
89Mio.

Largest Shareholders

Institutions

Institutions SNDX
Name Stake (%) Shares Change (%) Date
BlackRock Inc 9.32 8,254,426 +0.2 03/31/2026
Kynam Capital Management, LP 9.09 8,050,959 +0.0 03/31/2026
The Goldman Sachs Group Inc 5.64 4,996,787 -12.3 03/31/2026
State Street Corp 5.00 4,430,076 -3.6 03/31/2026
Bank of America Corp 4.80 4,249,836 -9.8 03/31/2026
Vanguard Capital Management, LLC 4.31 3,822,579 +0.0 03/31/2026
Deerfield Management Co 4.27 3,779,900 +0.0 03/31/2026
Eversept Partners, LP 3.26 2,885,622 -12.9 03/31/2026

Funds

Funds SNDX
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 3.90 3,455,413 -1.0 07/30/2026
Vanguard Morn Total Stk Mkt Idx Investor 3.19 2,825,144 +0.5 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
8. Jul 2026 Metzger Michael A Chief Executive Officer Sell 32,375 24.24 784,776
8. Jul 2026 Metzger Michael A Chief Executive Officer Other 32,375 6.38 206,553

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?